Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is one of the hematological malignancies. With the applications of chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the cure rate of T-ALL has been significantly improved. However, patients with relapsed and refractory T-ALL still lack effective treatment options. Gene mutations play an important role in T-ALL. The NOTCH1 gene mutation is the important one among these genetic mutations. Since the mutation of NOTCH1 gene is considered as a driving oncogene in T-ALL, targeting the NOTCH1 signaling patheway may be an effective option to overcome relapsed and refractory T-ALL. This review mainly summarizes the recent research advances of targeting on NOTCH1 signaling pathway in T-ALL.
Author supplied keywords
Cite
CITATION STYLE
Zheng, R., Li, M., Wang, S., & Liu, Y. (2020, December 1). Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia. Experimental Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s40164-020-00187-x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.